Western blot analysis of B-lymphoma moloney murine insertion region (BMI-1) and vascular endothelial growth factor (VEGF) when utilizing imiquimod and/ or bevacizumab treatment on DMBA induced hamster buccal pouch carcinoma | ||||
| Al-Azhar Journal of Dental Science | ||||
| Volume 27, Issue 4, October 2024, Page 523-534 PDF (1.78 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ajdsm.2022.174502.1383 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
amr elshamy  1; Emad Soliman Mohammed2; Mohammed Gomaa Zouair3; bakheet elkot4
| ||||
| 1oral and Dental Pathology Department, Faculty of Dental Medicine (Boys- Cairo), Al-Azhar University, Egypt. | ||||
| 2Oral pathology dept.Faculty of dental medicine, AlAzhar University, Cairo, Egypt | ||||
| 3Chairman of Oral and Dental Pathology Department, Al-Azhar University (Boys), Cairo,Egypt | ||||
| 4Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, (Boys-Assiut), Al-Azhar University, Egypt. | ||||
| Abstract | ||||
| Purpose of this research was to study how immunotherapy and bevacizumab affected cancer stem cell(s) (CSC(s)) in induced hamsters buccal pouch (HBP) carcinoma. Material and methods: 50 hamsters were split into 5 groups. Animals in GI were left untreated for 19 weeks (ws), the right pouches of those belongs to (GII- GV) were painted with 7,12- dimethylbenz (a) anthracene (DMBA), 3times a week for 14 ws, then, the following was done: GII was left with no additional treatment for other 5 ws, whereas GIII was painted with imiquimod once daily for other 4 ws, Those in GIV were injected intraperitoneally (IP) with bevacizumab (10mg/kg / once daily for a week), and those in GV were painted with imiquimod similar to GIII in addition to IP injection with bevacizumab similar to GIV. Gross observations and tumor volume were recorded for each group. After slaughtering the animals, all right pouches were divided into two pieces, one of which was prepared for hematoxylin and eosin (H&E) stain. The other piece was used for western blot analysis for identification of CSCs using BMI-1stem cell marker and VEGF) antibody. Results: Western blot examination of BMI-1 and VEGF antibodies indicated a significantly significant (p-value < 0.001) discrepancy between GV and the subsequent; GIII and GIV. In comparison, BMI-1 showed a non-significant variation (p-value < 0.125) between GIII and GIV, but VEGF showed a very substantial difference (p-value < 0.001). Conclusion: Combination of imiquimod-bevacizumab has an inhibitory effect on carcinoma cell and CSCs in HBP SCC | ||||
| Keywords | ||||
| HBP carcinoma; imiquimod; bevacizumab; CSCs | ||||
|
Statistics Article View: 107 PDF Download: 113 |
||||
